Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7986005 | 0.94 | ABCB1 (0.39) | ABCB1LMNACYP2C19HIF1ATDP1 | |
| SCHEMBL11387672 | 0.91 | ABCB1 (0.38) | ABCB1LMNACYP2C19HIF1ATDP1 | |
| SCHEMBL9009211 | 0.90 | ABCB1 (0.38) | ABCB1TDP1ARPOLBMAPK1 | |
| SCHEMBL1359798 | 0.84 | LMNA (0.38) | ABCB1LMNACYP2C19HIF1ATDP1 | |
| SCHEMBL8375500 | 0.84 | ABCB1 (0.37) | ABCB1LMNACYP2C19HIF1ATDP1 | |
| SCHEMBL8379840 | 0.82 | LMNA (0.39) | ABCB1LMNACYP2C19HIF1ATDP1 | |
| SCHEMBL17124727 | 0.82 | LMNA (0.41) | ABCB1LMNACYP2C19HIF1ATDP1 | |
| SCHEMBL12137490 | 0.82 | LMNA (0.37) | ABCB1LMNACYP2C19HIF1ATDP1 | |
| SCHEMBL9515975 | 0.82 | ABCB1 (0.37) | ABCB1LMNACYP2C19HIF1ATDP1 | |
| SCHEMBL28880448 | 0.81 | LMNA (0.36) | ABCB1LMNACYP2C19HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116354842-A | Improved preparation method of iomeprol and application of iomeprol in preparation | 重庆圣华曦药业股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-115160174-A | Synthesis method of ioversol | 浙江海洲制药有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-116354842-B | Improved preparation method of iomeprol and application of iomeprol in preparation | 重庆圣华曦药业股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-116354842-A | Improved preparation method of iomeprol and application of iomeprol in preparation | 重庆圣华曦药业股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-115160174-A | Synthesis method of ioversol | 浙江海洲制药有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20070014731-A1 | Contrast agents | GE HEALTHCARE | 2007-01-18 | — | — | US | disclosed |
| US-6106806-A | DIAGNOTIC ULTRASOUND; BIODEGRADABLE | NYCOMED IMAGING AS (NO) | 2000-08-22 | — | — | US | disclosed |
| WO-1991011431-A1 | PROCESS FOR PRODUCTION OF IOVERSOL | MALLINCKRODT, INC. (US) | 1991-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070014731-A1 | Contrast agents | FABP3, ANXA4, ANXA5 | ABCB1 842/4885LMNA 1902/4885CYP2C19 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.